{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:11:57Z","timestamp":1785795117808,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004179","name":"Ningxia Medical University","doi-asserted-by":"publisher","award":["XT2023025"],"award-info":[{"award-number":["XT2023025"]}],"id":[{"id":"10.13039\/501100004179","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21867016"],"award-info":[{"award-number":["21867016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404405"],"award-info":[{"award-number":["82404405"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360676"],"award-info":[{"award-number":["82360676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["KFKT202311"],"award-info":[{"award-number":["KFKT202311"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2022AAC05031"],"award-info":[{"award-number":["2022AAC05031"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2023AAC03239"],"award-info":[{"award-number":["2023AAC03239"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2024AAC03291"],"award-info":[{"award-number":["2024AAC03291"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2023AAC03186"],"award-info":[{"award-number":["2023AAC03186"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004772","name":"Natural Science Foundation of Ningxia Province","doi-asserted-by":"publisher","award":["2024AAC03351"],"award-info":[{"award-number":["2024AAC03351"]}],"id":[{"id":"10.13039\/501100004772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118066","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:20:35Z","timestamp":1755498035000},"page":"118066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Discovery of protein arginine methyltransferase 1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular dynamics simulations, and the enhancement of paclitaxel's antitumor activity"],"prefix":"10.1016","volume":"299","author":[{"given":"Yan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wun-Taai","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Mei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118066_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118066_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","article-title":"Pathology of triple negative breast cancer","volume":"72","author":"Borri","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118066_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118066_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ejmech.2025.118066_bib5","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.ejmech.2025.118066_bib6","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"ESMO guidelines committee, primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118066_bib7","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","article-title":"First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients","volume":"24","author":"Miles","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118066_bib8","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/annonc\/mdy201","article-title":"tnAcity investigators, nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial","volume":"29","author":"Yardley","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118066_bib9","unstructured":"E. Gobbini, M. Ezzalfani, V. Dieras, T. Bachelot, E. Brain, M. Debled, W. Jacot, M.A. Mouret-Reynier, A. Goncalves, F. Dalenc, A. Patsouris, J.M. Ferrero, C. Levy, V. Lorgis, L. Vanlemmens, C. Lefeuvre-Plesse, S. Mathoulin-Pelissier, T. Petit, L. Uwer, C. Jouannaud, M. Leheurteur, M. Lacroix-Triki, A.L. Cleaud, M. Robain, C. Courtinard, C. Cailliot, D. Perol, S. Delaloge, Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort, Eur. J. Cancer(n.d.)."},{"key":"10.1016\/j.ejmech.2025.118066_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bbacli.2015.03.003","article-title":"The fate of chemoresistance in triple negative breast cancer (TNBC)","volume":"3","author":"O'Reilly","year":"2015","journal-title":"BBA Clin."},{"key":"10.1016\/j.ejmech.2025.118066_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.biopha.2017.02.038","article-title":"Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-\u03baB signaling and regulating Bax\/Bcl-2 expression on triple-negative breast cancer","volume":"89","author":"Yuan","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118066_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12935-016-0290-9","article-title":"Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy","volume":"16","author":"Xu","year":"2016","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2025.118066_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ceb.2013.01.001","article-title":"Targeting histone modifications--epigenetics in cancer","volume":"25","author":"Waldmann","year":"2013","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118066_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12282-017-0790-z","article-title":"The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells","volume":"25","author":"Nakai","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejmech.2025.118066_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118066_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116887","article-title":"Overview of PRMT1 modulators: inhibitors and degraders","volume":"279","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118066_bib17","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.7150\/thno.42345","article-title":"PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.118066_bib18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1158\/0008-5472.CAN-23-2266","article-title":"PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer","volume":"84","author":"Yamamoto","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118066_bib19","doi-asserted-by":"crossref","first-page":"23892","DOI":"10.1074\/jbc.M401853200","article-title":"Small molecule regulators of protein arginine methyltransferases","volume":"279","author":"Cheng","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118066_bib20","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1021\/jm061250e","article-title":"Target-based approach to inhibitors of histone arginine methyltransferases","volume":"50","author":"Spannhoff","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118066_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4049\/jimmunol.1402465","article-title":"PRMT1 upregulated by epithelial proinflammatory cytokines participates in COX2 expression in fibroblasts and chronic antigen-induced pulmonary inflammation","volume":"195","author":"Sun","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118066_bib22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118066_bib23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1021\/acschembio.5b00839","article-title":"Selective, and cell-active inhibitor of human type I protein arginine methyltransferases","volume":"11","author":"Eram","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118066_bib24","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20171533","article-title":"Protein arginine methyltransferase expression and activity during myogenesis","volume":"38","author":"Shen","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejmech.2025.118066_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cmdc.200800301","article-title":"Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors","volume":"4","author":"Heinke","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118066_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliver. Rev."},{"key":"10.1016\/j.ejmech.2025.118066_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2025.118066_bib28","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2025.118066_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41419-023-05752-w","article-title":"PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118066_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.saa.2015.05.013","article-title":"Molecular structure, spectroscopic characterization, HOMO and LUMO analysis of 3,3\u2032-diaminobenzidine with DFT quantum chemical calculations","volume":"150","author":"Karabacak","year":"2015","journal-title":"Spectrochim. Acta"},{"key":"10.1016\/j.ejmech.2025.118066_bib31","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug Design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.118066_bib32","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0960-9822(01)00294-9","article-title":"Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1","volume":"11","author":"Strahl","year":"2001","journal-title":"Curr. Biol."},{"issue":"24","key":"10.1016\/j.ejmech.2025.118066_bib33","first-page":"323","article-title":"A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer","volume":"S2451\u20139456","author":"Zhang","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118066_bib34","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1092053","article-title":"Cell migration: integrating signals from front to back","volume":"302","author":"Ridley","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118066_bib35","series-title":"Gaussian, Inc.","author":"Gaussian","year":"2016"},{"key":"10.1016\/j.ejmech.2025.118066_bib36","doi-asserted-by":"crossref","first-page":"20323","DOI":"10.1039\/D1CP02805G","article-title":"Efficient evaluation of electrostatic potential with computerized optimized code","volume":"23","author":"Zhang","year":"2021","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejmech.2025.118066_bib37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118066_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.ejmech.2025.118066_bib39","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"6","author":"Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118066_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:53:36Z","timestamp":1772808816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["S0223523425008311"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118066","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of protein arginine methyltransferase 1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular dynamics simulations, and the enhancement of paclitaxel's antitumor activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118066"}}